GlassScriptPhysician profile
James A Humphrey
NPI 1992816615
$15,903.95
in general payments reported to CMS, 2019-2025
41 companies · $20.22 in 2025
The $20.22 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,704 · 2020: $2,275 · 2021: $2,690 · 2022: $3,429 · 2023: $3,342 · 2024: $444 · 2025: $20.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,787 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,786.60 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,522.93 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $2,279.84 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,879.42 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,253.28 | 2021-2024 | |
| Lilly USA, LLC | $993.12 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $954.96 | 2019-2023 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $832.63 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $738.25 | 2019-2022 | |
| Pfizer INC. | $671.40 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $627.70 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $347.48 | 2022-2025 | |
| Amgen INC. | $340.00 | 2019-2024 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $333.84 | 2019-2023 | Rexulti |
| Dexcom, INC. | $252.31 | 2021-2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $226.21 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Humphrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.